Ronald J. Sokol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ronald J. Sokol has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Eric Gumpricht
Isagenix International LLC, Gilbert, AZ 85297, USA
8 shared publications Rolf Dahl
Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora
8 shared publicationsMichael W Devereaux
Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora
4 shared publicationsBaruch Yerushalmi
Pediatric Liver Center Section of Pediatric Gastroenterology, Hepatology and Nutrition Department of Pediatrics University of Colorado School of Medicine Denver Colorado
3 shared publicationsMichael W. Devereaux
Pediatric Liver Center and Liver Transplantation Program, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Colorado at Denver Health Sciences Center, Denver, CO
3 shared publicationsCara Mack
2 shared publications
Latest Publications
- Open Access
- 23 May 2013
- Published by Wolters Kluwer Health in Hepatology
- Vol. 58 (5) , 1724-1731
Extrahepatic Anomalies in Infants With Biliary Atresia: Results of a Large Prospective North American Multicenter Study
The etiology of biliary atresia (BA) is unknown. Given that patterns of anomalies might provide etiopathogenetic clues, we used data from the North American Childhood Liver Disease Research and Education Network to analyze patterns of anomalies in infants with BA. In all, 289 infants who were enrolled in the prospective database prior to surgery at any of 15 participating centers were evaluated. Group 1 was nonsyndromic, isolated BA (without major malformations) (n = 242, 84%), Group 2 was BA and at least one malformation considered major as defined by the National Birth Defects Prevention Study but without laterality defects (n = 17, 6%). Group 3 was syndromic, with laterality defects (n = 30, 10%). In the population as a whole, anomalies (either major or minor) were most prevalent in the cardiovascular (16%) and gastrointestinal (14%) systems. Group 3 patients accounted for the majority of subjects with cardiac, gastrointestinal, and splenic anomalies. Group 2 subjects also frequently displayed cardiovascular (71%) and gastrointestinal (24%) anomalies; interestingly, this group had genitourinary anomalies more frequently (47%) compared to Group 3 subjects (10%). Conclusion: This study identified a group of BA (Group 2) that differed from the classical syndromic and nonsyndromic groups and that was defined by multiple malformations without laterality defects. Careful phenotyping of the patterns of anomalies may be critical to the interpretation of both genetic and environmental risk factors associated with BA, allowing new insight into pathogenesis and/or outcome. (Hepatology 2013;58:1724–1731)
- 23 May 2013
- Published by Wolters Kluwer Health in Hepatology
- Vol. 58 (5) , 1724-1731
Open AccessExtrahepatic Anomalies in Infants With Biliary Atresia: Results of a Large Prospective North American Multicenter Study
The etiology of biliary atresia (BA) is unknown. Given that patterns of anomalies might provide etiopathogenetic clues, we used data from the North American Childhood Liver Disease Research and Education Network to analyze patterns of anomalies in infants with BA. In all, 289 infants who were enrolled in the prospective database prior to surgery at any of 15 participating centers were evaluated. Group 1 was nonsyndromic, isolated BA (without major malformations) (n = 242, 84%), Group 2 was BA and at least one malformation considered major as defined by the National Birth Defects Prevention Study but without laterality defects (n = 17, 6%). Group 3 was syndromic, with laterality defects (n = 30, 10%). In the population as a whole, anomalies (either major or minor) were most prevalent in the cardiovascular (16%) and gastrointestinal (14%) systems. Group 3 patients accounted for the majority of subjects with cardiac, gastrointestinal, and splenic anomalies. Group 2 subjects also frequently displayed cardiovascular (71%) and gastrointestinal (24%) anomalies; interestingly, this group had genitourinary anomalies more frequently (47%) compared to Group 3 subjects (10%). Conclusion: This study identified a group of BA (Group 2) that differed from the classical syndromic and nonsyndromic groups and that was defined by multiple malformations without laterality defects. Careful phenotyping of the patterns of anomalies may be critical to the interpretation of both genetic and environmental risk factors associated with BA, allowing new insight into pathogenesis and/or outcome. (Hepatology 2013;58:1724–1731)
- 1 January 2010
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 50 (1) , 9-10
Reloading Against Rare Liver Diseases
- 1 January 2010
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 50 (1) , 9-10
Reloading Against Rare Liver Diseases
- 1 November 2009
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 49 (5) , 607-612
Pulmonary Vascular Complications in Asymptomatic Children With Portal Hypertension
Objectives: To determine the prevalence of portopulmonary hypertension, hepatopulmonary syndrome (HPS), and intrapulmonary vascular shunting (IPVS) in children with clinically stable portal hypertension and to assess the value of vasoactive peptide levels, biochemical tests and clinical signs or symptoms to predict these conditions.Patients and Methods: A prospective, cross‐sectional analysis was conducted on 33 children, ages 4 to 17 years, with stable cirrhosis (n = 28) or extrahepatic portal hypertension (n = 5). The children were screened for IPVS and hypoxia with contrast‐enhanced echocardiography (cECHO) and pulse oximetry, and screened for pulmonary hypertension with Doppler echocardiography. Chemistries, radiographs, physical examinations, and levels of vasoactive peptides were compared between subjects with IPVS and those with normal cECHO.Results: No subject had pulmonary hypertension. Six (19%) had IPVS, all of which had intrahepatic causes of portal hypertension, and 1 of whom had HPS. Compared with subjects with normal cECHO, those with IPVS had biochemical evidence of more advanced liver disease and higher b‐type natriuretic peptide levels.Conclusions: Prevalence of portopulmonary hypertension and HPS appear to be rare in clinically stable children with portal hypertension. Intrapulmonary vascular shunting was present in 19% of these patients. A novel finding of this study is the elevation of b‐type natriuretic peptide in children with IPVS.
- 1 November 2009
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 49 (5) , 607-612
Pulmonary Vascular Complications in Asymptomatic Children With Portal Hypertension
Objectives: To determine the prevalence of portopulmonary hypertension, hepatopulmonary syndrome (HPS), and intrapulmonary vascular shunting (IPVS) in children with clinically stable portal hypertension and to assess the value of vasoactive peptide levels, biochemical tests and clinical signs or symptoms to predict these conditions.Patients and Methods: A prospective, cross‐sectional analysis was conducted on 33 children, ages 4 to 17 years, with stable cirrhosis (n = 28) or extrahepatic portal hypertension (n = 5). The children were screened for IPVS and hypoxia with contrast‐enhanced echocardiography (cECHO) and pulse oximetry, and screened for pulmonary hypertension with Doppler echocardiography. Chemistries, radiographs, physical examinations, and levels of vasoactive peptides were compared between subjects with IPVS and those with normal cECHO.Results: No subject had pulmonary hypertension. Six (19%) had IPVS, all of which had intrahepatic causes of portal hypertension, and 1 of whom had HPS. Compared with subjects with normal cECHO, those with IPVS had biochemical evidence of more advanced liver disease and higher b‐type natriuretic peptide levels.Conclusions: Prevalence of portopulmonary hypertension and HPS appear to be rare in clinically stable children with portal hypertension. Intrapulmonary vascular shunting was present in 19% of these patients. A novel finding of this study is the elevation of b‐type natriuretic peptide in children with IPVS.
- 24 July 2009
- Published by Springer Nature in Current Hepatitis Reports
- Vol. 8 (3) , 96-102
Treatment of chronic hepatitis B virus infection in children
- 24 July 2009
- Published by Springer Nature in Current Hepatitis Reports
- Vol. 8 (3) , 96-102
Treatment of chronic hepatitis B virus infection in children
- 1 May 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 123 (5) , e951-e952
Biliary Atresia Screening: Why, When, and How?
- 1 May 2009
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 123 (5) , e951-e952
Biliary Atresia Screening: Why, When, and How?
- Open Access
- 1 November 2008
- Published by Springer Nature in Pediatric Research
- Vol. 64 (5) , 498-504
Resistance of Young Rat Hepatic Mitochondria to Bile Acid-Induced Permeability Transition: Potential Role of α-Tocopherol
Retention of bile acids within the liver is a primary factor in the pathogenesis of cholestatic liver disorders, which are more common in human infants. The objective of this study was to evaluate developmental changes in mitochondrial factors involved in bile acid-induced hepatocyte injury. Hepatic mitochondria from adult rats (aged 9 wk) underwent a mitochondrial permeability transition (MPT) and release of cytochrome c upon exposure to glycochenodeoxycholic acid. In contrast, mitochondria from young rats (age 6–36 d) were resistant to MPT induction and cytochrome c release. Neither mitochondrial levels of MPT-associated proteins (voltage-dependent anion channel, cyclophilin D, or adenine nucleotide translocase), Bcl-2 family proteins, nor antioxidant enzymes explained this resistance. Mitochondria from young rats contained 2- to 3-fold higher α-tocopherol (α-TH). In vivo α-TH enrichment of adult hepatic mitochondria increased their MPT resistance. Tetra-linoleoyl cardiolipin (TL-CL), the primary molecular species of CL, was reduced in mitochondria of the young rat; however, enrichment with CL and TL-CL only modestly increased their MPT susceptibility. In conclusion, we observed an unexpected resistance in young rats to bile acid induction of mitochondrial cell death pathways, which may be related to developmental differences in membrane composition.
- 1 November 2008
- Published by Springer Nature in Pediatric Research
- Vol. 64 (5) , 498-504
Open AccessResistance of Young Rat Hepatic Mitochondria to Bile Acid-Induced Permeability Transition: Potential Role of α-Tocopherol
Retention of bile acids within the liver is a primary factor in the pathogenesis of cholestatic liver disorders, which are more common in human infants. The objective of this study was to evaluate developmental changes in mitochondrial factors involved in bile acid-induced hepatocyte injury. Hepatic mitochondria from adult rats (aged 9 wk) underwent a mitochondrial permeability transition (MPT) and release of cytochrome c upon exposure to glycochenodeoxycholic acid. In contrast, mitochondria from young rats (age 6–36 d) were resistant to MPT induction and cytochrome c release. Neither mitochondrial levels of MPT-associated proteins (voltage-dependent anion channel, cyclophilin D, or adenine nucleotide translocase), Bcl-2 family proteins, nor antioxidant enzymes explained this resistance. Mitochondria from young rats contained 2- to 3-fold higher α-tocopherol (α-TH). In vivo α-TH enrichment of adult hepatic mitochondria increased their MPT resistance. Tetra-linoleoyl cardiolipin (TL-CL), the primary molecular species of CL, was reduced in mitochondria of the young rat; however, enrichment with CL and TL-CL only modestly increased their MPT susceptibility. In conclusion, we observed an unexpected resistance in young rats to bile acid induction of mitochondrial cell death pathways, which may be related to developmental differences in membrane composition.
- 1 October 2008
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 6 (10) , 1140-1145
Evaluation of a Scoring System for Assessing Prognosis in Pediatric Acute Liver Failure
- 1 October 2008
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 6 (10) , 1140-1145
Evaluation of a Scoring System for Assessing Prognosis in Pediatric Acute Liver Failure
- 24 June 2008
- Published by Springer Nature in Nature Clinical Practice Gastroenterology & Hepatology
- Vol. 5 (8) , 456-468
Mechanisms of Disease: inborn errors of bile acid synthesis
Inborn errors of bile acid synthesis can present as neonatal cholestasis, neurologic disease or fat-soluble-vitamin deficiencies. In this Review, the authors discuss what we now know about the mechanisms underlying these disorders thanks to the application of modern biochemical and molecular techniques, the importance of early diagnosis, and the treatment options currently available. Inborn errors of bile acid synthesis are rare genetic disorders that can present as neonatal cholestasis, neurologic disease or fat-soluble-vitamin deficiencies. There are nine known defects of bile acid synthesis, including oxysterol 7α-hydroxylase deficiency, Δ4-3-oxosteroid-5β-reductase deficiency, 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency, cerebrotendinous xanthomatosis (also known as sterol 27-hydroxylase deficiency), α-methylacyl-CoA racemase deficiency, and Zellweger syndrome (also known as cerebrohepatorenal syndrome). These diseases are characterized by a failure to produce normal bile acids and an accumulation of unusual bile acids and bile acid intermediaries. Individuals with inborn errors of bile acid synthesis generally present with the hallmark features of normal or low serum bile acid concentrations, normal γ-glutamyl transpeptidase concentrations and the absence of pruritus. Failure to diagnose any of these conditions can result in liver failure or progressive chronic liver disease. If recognized early, many patients can have a remarkable clinical response to oral bile acid therapy.
- 24 June 2008
- Published by Springer Nature in Nature Clinical Practice Gastroenterology & Hepatology
- Vol. 5 (8) , 456-468
Mechanisms of Disease: inborn errors of bile acid synthesis
Inborn errors of bile acid synthesis can present as neonatal cholestasis, neurologic disease or fat-soluble-vitamin deficiencies. In this Review, the authors discuss what we now know about the mechanisms underlying these disorders thanks to the application of modern biochemical and molecular techniques, the importance of early diagnosis, and the treatment options currently available. Inborn errors of bile acid synthesis are rare genetic disorders that can present as neonatal cholestasis, neurologic disease or fat-soluble-vitamin deficiencies. There are nine known defects of bile acid synthesis, including oxysterol 7α-hydroxylase deficiency, Δ4-3-oxosteroid-5β-reductase deficiency, 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency, cerebrotendinous xanthomatosis (also known as sterol 27-hydroxylase deficiency), α-methylacyl-CoA racemase deficiency, and Zellweger syndrome (also known as cerebrohepatorenal syndrome). These diseases are characterized by a failure to produce normal bile acids and an accumulation of unusual bile acids and bile acid intermediaries. Individuals with inborn errors of bile acid synthesis generally present with the hallmark features of normal or low serum bile acid concentrations, normal γ-glutamyl transpeptidase concentrations and the absence of pruritus. Failure to diagnose any of these conditions can result in liver failure or progressive chronic liver disease. If recognized early, many patients can have a remarkable clinical response to oral bile acid therapy.
- 1 March 2008
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 46 (3) , 238-240
Swiss Outcomes in Biliary Atresia: Are There Lessons to Be Learned?
- 1 March 2008
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 46 (3) , 238-240
Swiss Outcomes in Biliary Atresia: Are There Lessons to Be Learned?
- Open Access
- 28 November 2007
- Published by Wolters Kluwer Health in Hepatology
- Vol. 46 (6) , 1675-1678
Corticosteroid treatment in biliary atresia: Tonic or toast?
- 28 November 2007
- Published by Wolters Kluwer Health in Hepatology
- Vol. 46 (6) , 1675-1678
Open AccessCorticosteroid treatment in biliary atresia: Tonic or toast?